Evidence mapPaperPMID 41750568Full record

ReviewAntioxidants (Basel, Switzerland)2026

Sources of Oxidative Stress in Parkinson's Disease: Pathways and Therapeutic Implications.

Yordan Yordanov, Denitsa Stefanova, Magdalena Kondeva-Burdina, Virginia Tzankova

Abstract readReview
In one paragraph

Review in Antioxidants (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yordan YordanovDepartment of Pharmacology, Pharmacotherapy and Toxicology, Faculty of Pharmacy, Medical University of Sofia, Dunav 2 Str., 1000 Sofia, Bulgaria.ORCID 0000-0003-1029-9870
Denitsa StefanovaDepartment of Pharmacology, Pharmacotherapy and Toxicology, Faculty of Pharmacy, Medical University of Sofia, Dunav 2 Str., 1000 Sofia, Bulgaria.ORCID 0000-0002-6859-9369
Magdalena Kondeva-BurdinaDepartment of Pharmacology, Pharmacotherapy and Toxicology, Faculty of Pharmacy, Medical University of Sofia, Dunav 2 Str., 1000 Sofia, Bulgaria.
Virginia TzankovaDepartment of Pharmacology, Pharmacotherapy and Toxicology, Faculty of Pharmacy, Medical University of Sofia, Dunav 2 Str., 1000 Sofia, Bulgaria.

Funding

European Union NextGenerationEU through the National Recovery and Resilience Plan of the Republic of Bulgaria BG-RRP-2.004-0004-C01
6 · The paper itself

Abstract

Parkinson's disease (PD) is a heterogeneous neurodegenerative disorder in which oxidative stress represents a final common pathway linking diverse genetic and environmental insults to dopaminergic neuron loss. This review synthesizes evidence on how the commonly observed pathological changes in PD converge on excessive reactive oxygen species generation and redox imbalance. We present an overview on these pathways and key PD-linked genes that perturb mitochondrial quality control, lysosomal function, and inflammatory signaling, reinforcing oxidative stress. The major classes of redox-targeted therapeutic strategies under preclinical and clinical evaluation are outlined. Although many candidates show robust target engagement and neuroprotection in models, clinical trials have frequently yielded neutral or modest results, highlighting challenges related to brain delivery, off-target effects, optimal treatment window, and the fact that oxidative stress alone may be necessary but not sufficient to drive human disease progression. In the current paper, beyond cataloguing oxidative pathways, we explain the role of etiologic heterogeneity on biochemical target engagement and clinical outcomes. We outline subtype-enriched trial strategies and rational combination approaches. Targeting oxidative stress-related pathways thus remains a promising avenue for disease modification in PD, provided that future interventions are mechanistically informed and adapted to patient-specific redox vulnerabilities.

Indexed as

disease modifyingetiologynovel pharmacotherapyParkinson’s diseasepersonalized therapy

Identifiers

PMID41750568
PMCPMC12938284

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.